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ABSTRACT 
 
 
 
Background: The role of persistent organic pollutants (POPs) with endocrine disrupting activity in the aetiology of obesity and other metabolic dysfunctions has 
been recently highlighted. Adipose tissue (AT) is a common site of POPs accumulation where they can induce adverse effects on human health. 
Objectives:  To evaluate the presence of POPs in human visceral (vAT) and subcutaneous (scAT) adipose tissue in a sample of Portuguese obese patients that 
underwent bariatric surgery, and assess their putative association with metabolic disruption preoperatively, as well as with subsequent body mass index (BMI) 
reduction. 
Methods: AT samples (n¼ 189) from obese patients (BMI Z35) were collected and the levels of 13 POPs were determined by gas chromatography with electron-
capture detection (GC-ECD). Anthropometric and biochem- ical data were collected at the time of surgery. BMI variation was evaluated after 12 months and 
adipocyte size was measured in AT samples. 
Results:  Our data confirm that POPs are pervasive in this obese population (96.3% of detection on both  tissues), 
their abundance increasing with age (RS ¼ 0.310, po0.01) and duration of obesity (RS ¼ 0.170, po0.05). We observed a difference in AT depot POPs storage 
capability, with higher levels of ΣPOPs in vAT (213.97204.2 compared to 155.17147.4 ng/g of fat, po0.001), extremely relevant when evaluating their 
metabolic impact. 
Furthermore, there was a positive correlation between POP levels and the presence of metabolic syndrome components,   namely   dysglycaemia   and   
hypertension,   and   more   importantly   with   cardiovascular   risk (RS ¼ 0.277, po0.01), with relevance for vAT (RS ¼ 0.315, po0.01). Finally, we observed an 
interesting relation of higher POP levels with lower weight loss in older patients. 
Conclusion: Our sample of obese subjects allowed us to highlight the importance of POPs stored in AT on the development of metabolic dysfunction in a context 
of obesity, shifting the focus to their metabolic effects and not only for their  recognition as environmental    obesogens. 
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Introduction 
 
Central obesity is considered by some authors as a crucial 
component in the causal pathway of the metabolic syndrome 
(Palaniappan et al., 2004). The aetiology of obesity is multifactorial, 
but   whereas   energy   imbalance   is  mandatory,   many   agents may 
  
contribute to its establishment, including genetic and behavioural/ 
environmental factors (Newbold et al., 2008). Environmental condi- 
tions involving exposure to chemicals that even at very low doses 
have endocrine disruption  effects,  mimicking endogenous  hormones 
or modulating transcription factors, epigenetic mechanisms and 
endogenous hormone kinetics/availability, are proposed  for  a  num- 
ber of adverse human health effects, including infertility and cancers 
(Vandenberg et al., 2012, 2013; Valera et al., 2013; Sjoberg Lind et al., 
2013). 
Recent data correlated synthetic chemical production with 
obesity and  diabetes  prevalence  (Baillie-Hamilton,  2002; Neel 
and Sargis, 2011). These man-made chemicals are environmentally 
persistent since they have an intrinsic resistance to natural 
degradation processes, are lipophilic and  bioaccumulate  in  the 
food chain, being classified as persistent organic pollutants (POPs). 
Humans typically accumulate the highest POP concentrations in 
the adipose tissue (AT) (Ozonoff et al., 1994;  Li et al.,    2006). 
Considering the endocrine function of adipocytes and knowing 
that exposure to these chemicals disrupts  normal  development 
and homeostasis, resulting in obesity, these  chemicals  were 
termed  environmental  “obesogens” (Baillie-Hamilton,   2002; 
Grun and Blumberg, 2006). Hence, there is  a  growing  concern 
over a background exposure to POPs and the prevalence of 
metabolic syndrome (MetS), namely by the synergistic and simul- 
taneous  exposure  to  mixtures  of  POPs.  These  findings  raise the 
 
2.2. Clinical and biochemical parameters 
 
Anthropometrics, adiposity-related markers and various clinical variables were 
measured  preoperatively.  BMI  (kg/m
2
)  was  calculated  both  at  baseline  and  12 
months  post-surgery.  Blood  samples  were  collected  after  an  overnight  fast  and 
measures of  insulin  resistance (HOMA-IR)  and  beta-cell  function  (HOMA-B)  were 
calculated with the homeostatic model assessment (HOMA2) (Wallace et al., 2004). 
Routine  serum  chemistries  were  measured  using  conventional  methods  with  an 
Olympus  AU5400
s    
automated  clinical  chemistry  analyser  (Beckman-Coulter
s
, 
Izasa,  Porto,  Portugal).  Low-density  lipoprotein  (LDL)  cholesterol  was  calculated 
according to Friedewald's equation (Friedewald et al., 1972). Insulin was measured 
by  an  electrochemiluminescent  immunoassay  using  a  Cobas
s   
e411  automated 
analyzer   (Roche
s
,   Lisbon,   Portugal)   and   glycated   haemoglobin   (HbA1c)   was 
measured  with  an  ion-exchange  HPLC  system  with  a  D-10™  Bio-Rads   analyzer 
(Bio-Rad
s
, Porto, Portugal). 
The MetS components were classified according to the Harmonized Criteria 
(Alberti et al., 2009) that defined subjects with three or more of the following 
criteria as having MetS: (a) abdominal obesity (waist circumference Z 102 cm for 
men and 88 for women); (b) high triglycerides ( Z 150 mg/dL); (c) low HDL 
cholesterol ( o 40 mg/dL in men and o 50 mg/dL in women); (d) high blood 
pressure ( Z 130/85 mmHg); and (e) high fasting glucose ( Z 100 mg/dL). Treatment 
for any of these conditions was also considered a positive result. Lastly, we used the 
Framingham risk score to estimate the 10-year cardiovascular risk of these subjects 
(D’Agostino et al., 2008). 
 
 
2.3. Chemicals and reagents 
 
Formaldehyde   37%,   xylol,   entellan,   hematoxylin,   eosin   and   paraffin   were 
obtained   from   Merck
s    
(Darmastadt,   Germany).   Ethanol   solution   (EtOH)   was 
s 
possibility  that, in addition  to obesity  itself, some  POPs  stored in obtained  from Panreac (Barcelona, Spain) and n-hexane was purchased     from 
AT may be key to the pathogenesis of the MetS (Lee, 2007) 
especially when it remains puzzling why some people are more 
susceptible to develop MetS features or successful in losing weight 
(Freedland, 2004). Visceral and subcutaneous adipose tissues (vAT 
and scAT) display different metabolic properties, the first being a 
highly metabolically active tissue and apparently more susceptible 
to lipolysis (Freedland, 2004; Preis et al., 2010). Despite these 
differences, their putative dissimilar POPs storage capability and 
subsequent implications are still under discussion as duly raised 
by La Merrill et al. (2013) and other recent studies, however still 
with some restraints and insufficient to conclude this discussion 
(Malarvannan et al., 2013; Kim et al.,   2014). 
This study aimed to answer some of this issues, evaluating in a 
sample of Portuguese obese patients undergoing bariatric surgery, 
the levels of POPs in AT depots as well as their possible association 
with MetS comorbidities before surgery. In addition, we evaluated 
the relationship with the subsequent body mass index (BMI) 
reduction 12 months after surgery. For this purpose, we measured 
the levels of various POPs in two AT depots (vAT and scAT) and 
evaluated the relationships with MetS components and a variety 
of biological and clinical parameters   preoperatively. 
 
 
1. Materials and methods 
 
 
1.1. Study subjects 
 
A cohort of 189 obese men and women undergoing bariatric surgery for weight 
reduction at the General Surgery Department, S. João Hospital (Porto, Portugal), 
was recruited between January 2010 and June 2011. Patients met the criteria for 
obesity surgery [including BMI Z 40 kg/m
2
, or Z 35 kg/m
2 
with at least one 
comorbidity (hypertension, type 2 diabetes (T2DM), dyslipidaemia, or  obstructive 
sleep apnoea syndrome)] and signed informed consent to participate in the study. 
The study protocol was approved by the Hospital's Ethics Committee. Data 
regarding socio-demographic characteristics, clinical history, life-style factors, 
parity and occupation were collected from the hospital Medical Support System. 
Level of education was recorded as years of education, and then classified into four 
levels. Place of residence was defined according to the Eurostat degree of urbanization 
classification nomenclature (2011) into three categories (Eurostat, 2012). In turn, the 
subjects occupation was defined according to the Portuguese Occupation classification 
nomenclature (Instituto Nacional de Estatística, 2011), and was subsequently classified 
into three levels of occupation: white-collar (classes 0–4), blue-collar (classes 5–9) and 
without job (students and retired  subjects). 
Sigma-Aldrich
s    
(Madrid,   Spain).   The   POPs   aldrin,   dieldrin   and   endrin   were 
obtained  from  Pestanal  Fluka
s    
(Madrid,  Spain),  hexachlorobenzenene  (HCB)  and 
hexachlorocyclohexane lindane (HCH Lindane) were obtained from Pestanal Riedel-de 
Haën
s  
(Madrid, Spain), ∑ hexachlorocyclohexane (sum of α-HCH, β-HCH and δ-HCH) 
was   obtained   from   Sigma-Aldrich
s    
(Madrid,   Spain).   Endosulfan   I,   endosulfan   II, 
methoxyclor,   2,3,7,8-tetrachlorodibenzodioxin   (TCDD),   p,p0 -dichlorodiphenyldichlor- 
oethane (p,p0 -DDD) and p,p’-dichlorodiphenyltrichloroethane (o,p0 -DDT) were obtained 
from Supelco
s  
(Madrid, Spain). p,p0 -dichlorodiphenyldichloroethylene (p,p0 -DDE), was 
obtained from Chem Service
s  
(West Chester, United States of America (USA)). 
 
2.4. Adipose tissue sampling 
 
Human AT samples from two different depots were collected during bariatric 
surgery: vAT corresponded to omental fat and scAT to subcutaneous abdominal fat. 
After being excised, AT samples were coded, processed and divided into different 
portions and stored at  - 80 1C. 
 
2.5. Adipocyte size measurement 
 
A small portion of both ATs was fixed in buffered formaldehyde 10%, for at least 
48 h  (4 1C).  Following  fixation,  the  AT  was  dehydrated  and  finally  embedded  in 
paraffin. All samples were coded for a blind analysis and 3 mm-thick sections were 
obtained with a Leica
s  
Microtome (RM2125RT, Lisbon, Portugal), and stained with 
hematoxylin and eosin to assess morphology. Digital images were acquired with a 
fluorescence microscope (Nikon Eclipse 50i
s
, Melville, USA), at a magnification of 
x 200  from  five  randomly-selected  different  optical  fields.  Adipocyte  area  mea- 
surement  was  performed  with  ImajeJ  software
s   
(National  Institute  of  Health, 
Bethesda, USA). 
 
 
2.6. Determination of POPs in the AT 
 
POP analysis was performed according to the method described by Fernandes 
et al. (2012). The procedure included standardized extraction of 200 mg of AT, clean 
up using solid phase extraction columns Strata C18-E (SPE, 500 mg/3 mL, 55 mm), 
purchased   from   Phenomenex   (Torrance,   CA,   USA)   and   quantification   by   gas 
chromatography  with  electron-capture  detection  (GC-ECD)  a  Shimadzu  GC-2010, 
equipped  with  a  capillary  column  of  30 m  ZB-XLB  (0.25 mm  i.d.  0.25 μm  film 
thickness, Zebron-Phenomenex). 4-40 -dichlorobenzophenone was used as internal 
standard. The results were expressed as ng of POPs/g of fat and are a mean of three 
individual determinations of the same sample. 
 
 
2.7. Statistical analysis 
 
Standard descriptive statistics was used to describe the AT POP levels. Due to 
the lack of normal distribution, data were described as frequencies, median and 
respective interquartile range (IQR). The association between POPs concentration   in 
  
AT and  various parameters  was  analysed computing Spearman  correlation coeffi- 
cients, applied the Bonferroni multiple testing correction test when evaluating the 
effects  of  different POPs (significance  level was  considered for  p  values  o 0.001). 
The  Mann–Whitney,  Kruskal–Wallis  and  Wilcoxon  tests  were  used  to  compare 
median of POPs between groups. Additionally, t test was used to compare adipocyte 
area means in vAT and scAT and BMI variation between age groups. All probabilities 
were  two-tailed  and  p  values  o 0.05  were  regarded  as  significant.  All  statistical 
analyses  were  performed  using  Statistical  Package  for  Social  Sciences  (SPSS, 18.0 
version statistical software, IBM Corp.
s
, New York, USA). 
 
 
2. Results 
 
2.1. Descriptive characteristics 
 
The sociodemographic and lifestyle characteristics of the 
patients  are  shown  in  Supplementary  material,  Table  S1. These 
189   patients  with  an  age  range  of  19–65   years  (mean  age    of 
42.5710.9  years)  included  166  females  (88.7%).  Among  females, 
76.5% had children, being the mean number of children 1.67 1.1. 
Approximately  half  of  the  patients  lived  in  highly  populated 
areas in the north region of Portugal and at the moment of surgery 
the  mean  BMI  was  44.875.0 kg/m2.  Regarding  other  considered 
characteristics,  half  of  the  subjects  had  5–9  years  of  education 
or less (33.9% and 21.7%, respectively) and blue-collar occupation 
(43.4%).   Concerning   lifestyles,   most   of   the   subjects   did   not 
consume   alcoholic   beverages   or   smoked   (66.1%   and   75.2%, 
respectively). 
 
2.2. Distinct distribution of POP levels in vAT and scAT 
 
We examined the presence of the 13 tested POPs both in vAT 
and scAT samples (Table 1). After observing similar POPs distribu- 
tion between genders (data not shown), and due to the small 
number of male subjects, data was analysed without taking into 
account the gender. In both tissues, the percentage of samples 
with detectable concentrations of POPs was 96.3%, with median 
values of 172.9 (IQR 219.9) ng/g of fat in vAT and 116.1 (IQR 156.6) 
ng/g of fat in scAT, showing that virtually all patients had 
detectable quantities of these pollutants in the AT. 
The  most  ubiquitous  detected  POPs,  the  ΣHCH,  appeared  in 
91.5% and 89.9% of patients in the vAT and scAT with median values 
of 103.7 (IQR 147.2) ng/g of fat and 65.2 (IQR 145.4) ng/g of fat, 
respectively. With another distribution pattern, endosulfan II and 
methoxychlor  were  present unevenly  in both AT  types,  detected in 
28.0% and 61.9% of vAT samples, but only in 11.1% and 19.0% of scAT 
samples.  Regarding  DDT  and  its  metabolites,  the  percentage  of 
positive samples for this family of pesticides was 50.8% in both AT 
types. The highest contribution to their overall contamination came 
from the metabolite p,p0 -DDE, found in 29.1% of vAT and 33.3% of 
scAT samples, respectively with 22.6 (IQR 61.5) ng/g of fat and 2.8 
(IQR 10.3) ng/g of fat. 
To compare the vAT and scAT putative dissimilar POPs dis- 
tribution, POP levels present simultaneously in the two ATs of the 
same patient were compared (Table 2). The levels of ΣPOPs were 
positively correlated between both ATs (RS ¼ 0.632, p o 0.01), but 
the  concentration  in  vAT  was  significantly  higher   (213.97204.2 
compared  to  155.17147.4 ng/g  of  fat,  p o 0.001).  Regarding  the 
evaluated POPs, ΣHCH, HCB, endosulfan II, dieldrin and methoxy- 
chlor  were  positively  correlated  between  vAT  and  scAT.  On  the 
other hand, when comparing  the absolute concentration in each 
AT, higher concentrations of ΣHCH, ΣDDT/DDE/DDD, p,p0 -DDE and 
p,p0 -DDD were observed in vAT, contrasting with lower concentra- 
tions of HCB, aldrin and dieldrin. 
 
 
 
2.3. POP levels were associated with preoperative clinical and 
biochemical parameters of metabolic dysfunction 
 
The association between POP levels and the patient's clinical 
and biochemical parameters at baseline is presented in Table 3. 
The total ΣPOPs concentration in each subject was positively 
correlated with age, years of obesity evolution, HbA1c, urea  and 
systolic blood pressure. The observed correlations were similar 
when considering the ΣPOPs in vAT, however in scAT no correla- 
tion was found with obesity evolution and urea. Instead, ΣPOPs in 
scAT were positively correlated with HOMA-IR and diastolic blood 
pressure. The same analysis was conducted regarding the indivi- 
dual POPs (see Supplementary material, Tables S2 and S3). Among 
them, we emphasize the positive correlation of methoxychlor vAT 
levels with age, LDL cholesterol, glycaemia, HbA1c, ALT and urea 
and  of  p,p0-DDE  with  age  and  glucose  metabolism,  namely  with 
HbA1c.  Additionally,  we  examined  the  association  between  POP 
levels   and   adipocyte   size.   The   mean   adipocyte   size   in   scAT 
(63217 1501 mm2)   was   significantly   higher   compared   to   vAT 
(420671296 mm2; p o 0.0001) (see Supplementary material, Fig. 
S1). No significant correlation was found between the ƩPOPs levels 
and adipocyte size from the corresponding tissues. 
 
 
Table 1 
Detection of studied persistent organic pollutants (POPs) in visceral and subcutaneous adipose tissue (vAT and scAT) of the 189 patients. 
 
 
POPs vAT n %
a 
Median
b 
IQR
b 
POPs scAT n %
a 
Median
b 
IQR
b
 
 
ΣHCH 173 91.5 103.7 147.2 ΣHCH 170 89.9 65.2 145.4 
HCH Lindane 44 23.3 19.0 29.5 HCH Lindane 36 19.0 31.0 36.9 
HCB 18 9.5 64.7 30.7 HCB 17 9.0 72.2 30.4 
Aldrin 34 18.0 7.2 9.9 Aldrin 30 15.9 22.7 32.9 
Dieldrin 30 15.9 65.2 89.9 Dieldrin 26 13.8 45.1 96.9 
Endrin 6 3.2 284.8 322.7 Endrin 2 1.1 146.4  
Endosulfan  I 14 7.4 2.8 2.7 Endosulfan  I 6 3.2 47.0 94.3 
Endosulfan II 53 28.0 1.8 2.2 Endosulfan II 21 11.1 2.2 18.2 
TCDD 3 1.6 23.8  TCDD 6 3.2 24.6 29.7 
Methoxychlor 117 61.9 21.3 31.6 Methoxychlor 36 19.0 40.6 45.8 
ΣDDT/DDE/DDD 96 50.8 40.8 51.1 ΣDDT/DDE/DDD 96 50.8 5.7 29.3 
o,p0 -DDT 19 10.1 41.7 6.5 o,p0 -DDT 19 10.1 39.7 16.2 
p,p0 -DDE 55 29.1 22.6 61.5 p,p0 -DDE 63 33.3 2.8 10.3 
p,p0 -DDD 24 12.7 58.6 77.1 p,p0 -DDD 18 9.5 15.5 94.9 
ΣPOPs in vAT 182 96.3 172.9 219.9 ΣPOPs in scAT 182 96.3 116.1 156.6 
Total ΣPOPs 189 100.0 290.5 372.2 Maximum
b
 1668.3 Minimum
b
 5.3  
a  
Percentage of the total number of positive samples. 
b  
ng/g of fat; interquartile range (IQR). 
  
Table 2 
Comparison between levels of persistent organic pollutants (POPs) present simultaneously in both visceral (vAT) and subcutaneous adipose tissue (scAT). 
 
 
POPs n %
a 
Spearman's  correlation vAT vs. scAT (Wilcoxon  test) 
 
 (vAT and scAT)   vAT (Mean 7 SD)b scAT (Mean 7 SD)b p Value  
ΣHCH 155 82.0 0.540nn 121.1 7103.8 95.5786.6 0.003n  
HCH lindane 20 10.6 - 0.074 35.9774.6 50.2757.7 0.067  
HCB 17 9.0 0.669nn 74.97 31.0 83.1730.7 0.028n  
Aldrin 23 12.2 0.369 12.07 11.4 23.9725.3 0.008
n
  
Dieldrin 14 7.4 0.829
nn
 71.3 7 67.4 111.7 792.7 0.006
n
  
Endosulfan II 21 11.1 0.714nn 54.87116.3 60.27131.8 0.054  
Methoxychlor 30 15.9 0.372n 32.4718.5 33.9723.1 0.704  
Σ DDT/DDE/DDD 51 27.0 0.099 62.2768.7 36.9755.2 0.023n  
o,p0 -DDT 18 9.5 - 0.071 42.479.5 39.3713.6 0.420  
p,p0 -DDE 18 9.5 0.426 72.47108.9 18.5726.7 0.039n  
p,p0 -DDD 12 6.3 0.112 85.7733.3 35.9752.1 0.023n  
Σ POPs 175 92.6 0.632
nn
 213.97204.2 155.17 147.4 r 0.001
nn
  
a  
Percentage of the total number of positive samples in both AT—positive samples. 
b  
ng/g of fat; standard deviation (SD). Statistical analysis with Spearman's correlation and Wilcoxon test. 
n p o 0.05. 
nn p o 0.01. 
 
 
 
Table 3 
Clinical and biological characteristics of subjects at baseline and their correlation with sum of persistent organic pollutant (ƩPOP) levels in total, visceral (vAT) and 
subcutaneous  adipose  tissue (scAT). 
 
Parameters n Mean 7 SD ΣPOPs vAT ΣPOPs scAT Total ΣPOPs 
Age information      
Age (years) 189 42.5710.9 0.344nn 0.245nn 0.310nn 
Obesity evolution (years) 180 19.179.7 0.177n 0.085 0.170n 
Anthropometric parameters      
BMI (kg/m
2
) 189 44.875.0 0.039 0.041 0.045 
Waist circunference (cm) 158 123.0713.2 - 0.002 0.097 0.031 
vAT adipocyte area (mm
2
) 183 4218.071308.0 0.014  0.040 
scAT adipocyte area (mm
2
) 182 6312.071508.0  0.060 0.074 
Plasma lipid profile      
Total cholesterol (mg/dL) 189 205.3740.1 0.143 0.078 0.096 
Total triglycerides (mg/dL) 189 136.2761.0 0.055 0.068 0.052 
HDL  cholesterol (mg/dL) 189 50.8711.8 0.044 0.031 0.045 
LDL  cholesterol (mg/dL) 189 132.3732.1 0.100 0.095 0.091 
Plasma glucose homeostasis and insulin sensitivity 
Glycaemia (mg/dL) 189 100.1728.1 0.098 0.104 0.109 
HbA1c (%) 183 5.870.9 0.313nn 0.249nn 0.279nn 
HOMA-IR 165 2.57 1.6 - 0.042 0.174n 0.053 
HOMA2-B (%) 
Blood pressure 
165 156.6768.7 - 0.136 0.084 - 0.034 
Systolic blood pressure (mmHg) 148 136.6718.3 0.178
n
 0.209
n
 0.176
n
 
Diastolic blood pressure (mmHg) 148 82.7713.2 0.078 0.198n 0.123 
Cell  damage markers      
AST (U/L) 184 25.87 11.0 - 0.007 - 0.014 0.014 
ALT (U/L) 185 29.2717.4 0.059 0.080 0.086 
gGT (U/L) 182 38.3735.1 0.080 0.026 0.069 
ALP (U/L) 
Others parameters 
189 71.4720.2 0.031 - 0.024 0.023 
Urea (g/L) 189 34.579.6 0.248nn 0.124 0.199nn 
C-reactive protein (mg/L) 120 11.678.5 0.012 - 0.067 - 0.031 
Alanine aminotransferase (ALT); gamaglutamiltranspeptidase (gGT); alkaline phosphatase (ALP); aspartate aminotransferase (AST); body mass index (BMI); glycated 
haemoglobin (HbA1c); insulin resistance (HOMA-IR); beta-cell function (HOMA-B); standard deviation (SD). Statistical analysis with Spearman's correlation. 
n p o 0.05. 
nn p o 0.01. 
 
The relationship between POP levels and the prevalence of 
individual metabolic abnormalities and MetS in the patients was 
also assessed (Table 4). MetS was present in 65.8% of subjects. As 
for its components, 45.9% had high triglycerides, 54.6% reduced 
HDL cholesterol, 36.5% elevated fasting glucose and 79.5% had high 
blood  pressure.  Comparing  the  ΣPOP  levels  of  patients  with or 
without these metabolic abnormalities,  we  observed  that the 
levels  either  for  total  or  both  AT  types  tended  to  be  higher  in 
those with metabolic dysfunction. This difference was significant 
for  dysglycaemia,  with   particular   emphasis   for   vAT   ΣPOPs 
(p ¼ 0.001). Despite with a similar pattern, the difference in 
elevated blood pressure and MetS itself  was  not  significant  for 
vAT ΣPOPs (p ¼ 0.058 and p ¼ 0.091). 
Considering the number of MetS components present in each 
patient, the pattern of POPs distribution was once more different, 
especially  for  vAT  ΣPOPs  where  the  patients  with  more  MetS 
  
Table 4 
Prevalence of individual metabolic abnormalities and metabolic syndrome in the subjects at baseline and relation with sum of persistent organic pollutant (ƩPOP)  levels. 
 
Characteristics n (%) ΣPOPs vAT    ΣPOPs scAT    Total ΣPOPs  
 Mediana IQRa p Value  Mediana IQRa p Value  Mediana IQRa p Value  
Elevated triglycerides   0.119    0.220    0.245  
With 84 (45.9) 180.0 221.7   150.6 174.6   303.9 364.3   
Without 99 (54.1) 159.9 208.5   98.6 149.7   222.4 372.1   
Reduced HDL   0.257    0.479    0.308  
With 100 (54.6) 176.6 211.0   153.0 173.4   305.2 388.7   
Without 83 (45.4) 
Elevated fasting glucose 
169.8 192.6  
0.001nn 
 100.4 157.0  
0.022n 
 268.2 354.9  
0.002n 
 
With 69 (36.5) 223.3 270.7   162.4 187.2   356.7 445.2   
Without 120 (63.5) 140.6 189.2   95.3 146.1   220.4 380.2   
Elevated blood pressure   0.058    0.107    0.088  
With 132 (79.5) 182.6 215.5   127.7 163.2   300.7 366.1   
Without 34 (20.5) 118.6 202.8   65.1 165.6   182.6 352.5   
Metabolic syndrome   0.091    0.248    0.142  
With 121 (65.8) 179.1 210.7   139.9 162.9   299.0 377.8   
Without 63 (34.2) 
Number of components 
140.6 233.8  
0.008n 
 98.7 151.6  
0.111 
 202.5 368.1  
0.026n 
 
1 17 (9.2) 138.1 133.5   99.8 145.2   213.1 302.8   
2 46 (25.0) 139.9 252.6   85.5 152.8   199.4 394.9   
3 53 (28.8) 133.4 203.6   69.0 151.3   222.4 444.8   
4 44 (23.9) 194.8 233.6   134.8 143.3   303.7 268.3   
5 24 (13.0) 293.6 265.8   180.1 291.9   419.1 606.2   
n p o 0.05. 
nn p o 0.01. 
a 
ng/g of fat; interquartile range (IQR); visceral (vAT) and subcutaneous adipose tissue (scAT). Values are represented as median (IQR). Statistical analysis with Mann– 
Whitney and  Kruskal–Wallis tests. 
 
components had higher amounts of POPs (p ¼ 0.008). The analysis 
with individual POPs (see Supplementary material, Tables S4 and 
S5), did not fully replicate the results from the ΣPOP levels. Still, 
Table 5 
Spearman correlation coefficients (RS) of the 10-year estimate of cardiovascular risk 
(Framingham risk score) and the median levels of persistent organic pollutants 
(POPs). 
vAT methoxychlor levels were higher in patients with MetS  and    
 
 
 
 
 
 
 
causal pathway and the difficulty to isolate the independent effect 
of POPs. 
Lastly, using the Framingham risk score to estimate the 10-year 
cardiovascular risk (Table 5), we observed a positive correlation 
with the vAT ΣPOP levels (RS ¼ 0.315, p o 0.01), as well as with 
total and scAT levels (RS ¼ 0.227, p o 0.01 and RS ¼ 0.220, p o 0.05, 
respectively). Also in vAT, both methoxychlor and HCH   lindane 
Endosulfan I 12 0.336 0.286 5 
Endosulfan II 41 0.184 0.248 18 0.061 0.810 
TCDD 3 5 
strongly correlated with CVD risk (RS ¼ 0.447,  p o 0.01   and ΣPOPs per tissue     133 0.315
nn
 r 0.001   131 0.220n 0.012 
RS ¼ 0.479, p o 0.05 respectively). 
 
2.4. Putative relation between POPs concentration and weight loss 
depending on age group 
 
In order to explore the putative influence of POPs in the success 
of weight loss, the evaluation of BMI variation 12 months after 
surgery was addressed (Fig. 1). Older subjects (46–65 years) had, in 
addition to higher preoperative ΣPOP levels (total, vAT and scAT), a 
significantly smaller reduction of BMI after 12 months (19–45 years, 
12.5 70.6 kg/m2; 46–65 years, 9.770.5 kg/m2; p o 0.01). 
 
3. Discussion 
 
In this study we assessed the distribution of several POPs in 
human AT of an obese population, and subsequently its  association 
Total ΣPOPs 137 0.277nn 0.001 
 
 
Visceral (vAT) and subcutaneous adipose tissue (scAT). Statistical analysis with 
Spearman's correlation 
nn p o 0.01. 
 
 
with metabolic comorbidities, unravelling a putative involvement 
in the MetS. For this purpose, we analysed a sample of obese 
patients undergoing bariatric surgery. An important and novel 
evaluation was carried in this study, since by analysing two AT 
depots we were able to observe a dissimilar POPs distribution. 
Despite the accepted different metabolic properties of vAT and 
scAT (Freedland, 2004; Alessi et al., 1997), their storage propensity 
for these compounds was still not fully explored. Several studies 
admit that the distribution was similar in the two AT, offering the 
possibility of extrapolation from only one of the tissues (Kim et al., 
2011; Arrebola et al., 2010). However other authors point out the 
elevated fasting glucose and blood pressure, along with endosul- POPs vAT    scAT  
fan II for elevated fasting glucose and MetS. As for p,p0-DDE levels, 
they were higher both in vAT and scAT of patients with elevated 
 n RS p Value  n RS p Value  
fasting glucose. However, while not changing the directionality of 
ΣHCH 127 0.064 0.473  121 0.145 0.113  
the   associations,   when   we   adjusted   the   results   for   age,   no HCH Lindane 37 0.479nn 0.003  25 0.188 0.369  
significant associations were observed (see Supplementary mate- HCB 13 - 0.027 0.929  12 0.042 0.897  
rial,  Table  S6).  Nevertheless,  the  association  with  age  remained Aldrin 27 - 0.148 0.460  25 - 0.036 0.864  
significant in all models, supporting once more age as part of the 
Dieldrin 
Endrin 
25 
4 
0.351 0.085 
 
19 
2 
0.369 0.120 
 
 
Methoxychlor 87 0.447nn r 0.001 26 - 0.132 0.522 
ΣDDT/DDE/DDD 70 0.128 0.291 70 0.142 0.240 
o,p0 -DDT 13 0.077 0.803 14 0.495 0.072 
p,p0 -DDE 39 0.276 0.089 44 0.296 0.051 
p,p0 -DDD 19 - 0.223 0.359 14 0.103 0.725 
 
  
 
 
Fig. 1. Evaluation of body mass index (BMI) variation 12 months after surgery and preoperative persistent organic pollutant (POP) levels according to age groups, a younger 
(19–45 years) and the elder group (46–65 years): (A) BMI variation 12 months after surgery (mean 7 SEM); (B) sum of total POP (ƩPOP) levels (ng/g fat); (C) ΣPOP levels in 
visceral adipose tissue (vAT) and subcutaneous adipose tissue (scAT). Statistical analysis with t test (BMI variation) and Mann–Whitney test (POP levels): nnp o 0.01, 
nnnp o 0.001. 
 
importance of a comprehensive evaluation of the heterogeneity of 
POPs distribution (La Merrill et al., 2013), however the current 
studies are still insufficient mostly due to the normal methodolo- 
gical restraints posed by this type of research (Malarvannan et al., 
2013; Kim et al., 2014). The knowledge that the  distribution of 
POPs is different between vAT and scAT highlights the importance 
of being cautious when making extrapolations, but also that we 
could be missing distinct metabolic effects. Furthermore, these 
results could also help explain, at least in part, the different 
metabolic profiles of vAT and   scAT. 
Another important observation was that virtually all subjects 
had detectable quantities of these pollutants in the AT. So, 
considering the ΣPOP levels, despite with equal percentage of 
detection (96.3%) and positive correlations between vAT and scAT 
levels, the concentration was significantly higher in vAT.  This 
result is relevant since vAT is held as an highly metabolic active 
tissue and apparently more susceptible to lipolysis and conse- 
quently to POPs release (Alessi et al., 1997; Roos et al.,    2013). 
We also addressed the relationship between POP levels and the 
clinical and biochemical markers at baseline, not forgetting the 
putative effect of differences in vAT and scAT. Our study subjects 
were already a risk population for the MetS development, since 
they were morbidly obese patients undergoing bariatric surgery, a 
metabolic surgery, due to its contribution to effective resolution or 
great improvement of comorbidity risk factors, in addition to 
weight loss. Despite this fact, there is still no clear explanation 
why some of these patients develop the common comorbidities of 
obesity and others do not (Freedland, 2004), and the mechanisms 
responsible for differences in weight losses. First of all, we showed 
a strong positive correlation of age with ΣPOP levels (total, vAT 
and scAT), an evaluation of the overall burden of POPs. This 
association can be a result of the lipophilic and  bioaccumulative 
nature of POPs (Arrebola et al., 2010; Dirinck et al., 2011), 
corroborated by the same positive relation with years of obesity 
evolution, or a cohort effect, since older patients may have been 
more exposed to these compounds before they were banned. 
Another important observation confirmed by our data was that the 
ΣPOP levels related positively with glucose metabolism and blood 
pressure parameters, namely HbA1c and systolic blood pressure, 
comparable with results from other studies (Lee et al., 2007; Turyk 
et al., 2009). Moreover, scAT levels also correlated with   HOMA-IR 
(indicator of insulin resistance) and diastolic blood pressure. Once 
again, the ΣPOP levels in vAT seems to be more representative of 
total levels. Interestingly, these results showed a positive relation 
between POPs concentrations and glucose metabolism or    blood 
pressure parameters. However no relation was found with anthro- 
pometric parameters and lipid markers, probably based in the fact 
that obesity is already installed. Nevertheless, the association 
between BMI and POP levels is also still somehow controversial 
(Dirinck et al., 2011). 
Assuming that these POPs alter some MetS components, we 
assessed the relationship between POP levels and the prevalence 
of individual metabolic abnormalities and MetS. Of all patients, 
approximately 65.8% had MetS, demonstrating that even in mor- 
bidly obese patients there are differences in metabolic abnormal- 
ities and MetS prevalence. Substantiating the previous results, we 
observed that POP levels either in total or both AT types tended to 
be higher in those subjects with evidence of metabolic dysfunc- 
tion. This pattern was particularly evident in vAT, where adding to 
the significant difference in patients with elevated fasting glucose, 
the same tended to be true for elevated blood pressure and MetS 
itself. Nevertheless, the subjects with elevated fasting glucose had 
significantly higher POP levels regardless the considered AT depot. 
These results were similar as those described by Lee et al. (2011), 
  
where simultaneous exposure to various POPs contributed to 
development of obesity, dyslipidaemia, T2DM and CVD. Consider- 
ing that these individuals were all obese, we can speculate that 
POPs  exposure  may  contribute  to  these  dysmetabolism features, 
evidence supported by the higher vAT ΣPOP levels in patients with 
increased aggregation of MetS components.  Likewise,  possibly 
even more relevant in the prediction of the metabolic dysfunction 
effects, the evaluation of cardiovascular risk within 10 years 
through the Framingham score corroborated the association  of 
high concentrations of POPs with worse CVD prognosis, particu- 
larly considering the vAT. Indeed, a recent study regarding the 
possible relation of POPs in plasma with variation in the preva- 
lence of metabolic risk among obese individuals, corroborates the 
pertinence of our results (Gauthier et al., 2014). However, we 
explore POPs present in AT and as highlighted by La Merrill et al. 
(2013), AT is unequivocally a target of POPs and experimental 
research is confirming their relation with metabolic diseases and 
diabetes. 
Regarding  individual  POPs,  we  observed  distinct  behaviours. 
The compounds, ΣHCH, p,p0 -DDE, p,p0 -DDD and ΣDDT/DDE/DDD, 
had  a  similar  distribution  to  ΣPOPs.  The  levels  of  the  most 
ubiquitous,   ΣHCH,   also   showed   a   strong   positive   correlation 
between  vAT and  scAT,  and  along  with  HCH  lindane  were  posi- 
tively correlated with dysglycaemia and hypertension, the levels of 
the  last  in  vAT  being  also  strongly  correlated  with  CVD  risk. 
Regarding  DDT  and  its  metabolites,  there  was  no  correlation 
between  levels  in  vAT  and  scAT,  but  again  the  concentration  in 
vAT was higher. The main contribution to the overall contamina- 
tion with this group of compounds came from p,p0 -DDE, probably 
deriving from dietary exposure or from o,p0 -DDT metabolism, even 
after its use was banned in Portugal since 1988 (Fernandes et al., 
2011; Correia-Sa et al., 2012). As suggested in the literature (Turyk 
et  al.,  2009;  Lee  et  al.,  2011),  p,p0-DDE  is  closely correlated  with 
glucose  metabolism  impairment,  which  according  to  our  results 
seems to be more influenced by their presence in vAT. 
Moreover, the pesticides methoxychlor and endosulfan II had a 
different distribution pattern, with no differences in concentra- 
tions between tissues, but with higher percentage of positive 
samples in vAT. Methoxychlor, introduced with the intent of 
replacing DDT as a pesticide and recently also banned, was mainly 
detected in vAT from which its levels were correlated with worst 
glucose metabolism and lipid profile markers, plus cell damage 
markers and plasmatic urea. These relations support the preva- 
lence of metabolic abnormalities (elevated fasting  glucose  and 
blood pressure) and MetS, besides a strong correlation with CVD 
risk. In turn, higher levels of endosulfan II in vAT were present in 
patients with elevated fasting glucose and MetS. Finally, with 
similar low percentages of detection between tissues, we observed 
a higher concentration of HCB, aldrin and dieldrin in scAT. In brief, 
despite  the  similarity  with  the  overall  relations  observed  in the 
ΣPOPs, the analysis of individual POPs did not fully replicate them, 
differing between POPs and tissues, emphasizing the dissimilarity 
between analysing one compound alone or their mixture, an 
important discussion in current environmental health research. 
Adding to the relations with glucose metabolism and hypertension 
markers, we also observed a relationship with adiposity and lipid 
profile markers, as well as cell damage and inflammatory markers 
in plasma. 
This study also explored the relation between POP levels and 
adipocyte size. Obesity occurs by adipocyte hypertrophy or hyper- 
plasia. Hypertrophy seems to be the initial steps towards adipocyte 
cell dysfunction (Monteiro, 2009; Monteiro et al., 2006) and POPs 
action  on  these  mechanisms   may  promote  their    dysregulation 
(Grun and Blumberg, 2009; Wada et al., 2007). Our data did not 
reveal a correlation between the ΣPOP levels and adipocyte size 
from the corresponding tissue, probably because we analysed an 
obese population, and adipocytes are at the limit of lipid accumu- 
lation (Tan and Vidal-Puig, 2008; Virtue and Vidal-Puig, 2010). 
Additionally, recent studies reported that body weight change can 
affect serum and AT concentrations of POPs, suggesting that 
release of pollutants from AT could be related to increased lipolysis 
and therefore also associated with the magnitude of weight loss 
(Hue et al., 2006; Imbeault et al., 2001). In severely obese, as in 
other people, some are more successful in losing weight than 
others (Picot et al., 2009). In this study, the older subjects had a 
significantly smaller reduction of BMI after 12 months, in accordance 
with observations showing that patients’ age negatively associates 
with success in weight loss after bariatric surgery (Scozzari et al., 
2012;  Faria  et al.,  2014).  Interestingly,  in these  subjects,  we also 
observed higher preoperative ΣPOP levels. Apparently, these results 
are compatible with a relationship between severity of dysmetabo- 
lism and resistance to weight loss and high POPs concentration, with 
vAT as a better representative of the overall effect. Despite prelimin- 
ary, these results suggest an interesting association of surgery out- 
come success prediction, worthy of further research expanding to 
other  outcome  parameters. 
We acknowledge that the present study is not without limita- 
tions: (i) the patients were at the “end-of-line” of obesity treat- 
ment; (ii) lack of complementary analyses of plasma POP levels. 
Notwithstanding, our study has significant assets regarding the 
large sample size; the analyses of two different AT  depots,  the 
main accumulation site and probably the most affected tissue; and 
the possibility to evaluate weight loss after surgery. These assets 
allowed us a better understanding of POP effects on metabolic 
abnormalities. 
 
 
 
4. Conclusion 
 
In conclusion, the fact that almost all AT samples had detect- 
able levels of POPs provides ample reason for concern about the 
possible health effects of these compounds, even in countries with 
stricter regulations such as Portugal, under European legislation. 
Our study gives an important contribution for the elucidation of 
the dissimilar POPs storage capability of two metabolic distinct AT 
(vAT and scAT), where vAT appears more affected, particularly 
relevant when evaluating their metabolic impact. Furthermore, we 
observed a positive correlation between POP levels and metabolic 
abnormalities, namely with dysglycaemia and high blood pressure 
components of the MetS and most importantly with cardiovascu- 
lar risk, with some relevance for vAT. Our sample of obese subjects 
allowed us to highlight the importance of POPs in the metabolic 
dysregulation despite the presence of obesity, shifting the focus to 
their metabolic effects and not only for its recognition as environ- 
mental obesogens. Furthermore, AT POP levels could be a possible 
predictor of unsuccessful weight loss in obese patients, worthy of 
further research. These results underline the need for Portuguese, 
as well as global, public health authorities to evaluate the extent of 
human exposure to environmental contaminants and lifestyle factors 
associated  with  the  development  of  metabolic abnormalities. 
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